Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Go back to Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases| (NASDAQ: ALLO) | Delayed: 2.07 -0.03 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.10 | 52 Week High | $ | |||
| Open | $2.03 | 52 Week Low | $ | |||
| Day High | $2.17 | P/E | N/A | |||
| Day Low | $2.03 | EPS | $ | |||
| Volume | 4,811,704 | |||||
